•
Sep 30, 2024

TELA Bio Q3 2024 Earnings Report

TELA Bio's third quarter revenue reached a historic high, driven by strong product demand and normalized growth across the OviTex portfolio, while the company focused on commercial leadership and operating leverage.

Key Takeaways

TELA Bio reported a 26% increase in revenue to $19 million for the third quarter of 2024, marking a historic high. Gross profit was $12.9 million, or 68% of revenue. The company experienced a net loss of $10.4 million, and held $17.3 million in cash and cash equivalents as of September 30, 2024.

Third quarter revenue reached a historic high of $19 million, reflecting strong product demand.

Revenue increased by 26% compared to the same period in 2023, driven by increased unit sales and international growth.

Gross profit was $12.9 million, representing 68% of revenue.

The company is focused on commercial leadership and demonstrating increased operating leverage.

Total Revenue
$19M
Previous year: $15.1M
+25.9%
EPS
-$0.42
Previous year: -$0.45
-6.7%
Gross Profit
$12.9M
Previous year: $10.4M
+24.0%
Cash and Equivalents
$17.3M
Previous year: $58.2M
-70.3%
Free Cash Flow
-$9.11M
Previous year: -$7.1M
+28.2%
Total Assets
$53M
Previous year: $87.3M
-39.3%

TELA Bio

TELA Bio

Forward Guidance

TELA Bio reiterates its 2024 revenue guidance and anticipates reduced operating expenses in 2025 due to recently implemented operational efficiency improvements.